Publication Archives - Iterion Therapeutics https://iteriontherapeutics.com/category/publication/ Thu, 14 Sep 2023 19:49:02 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://iteriontherapeutics.com/wp-content/uploads/2023/09/cropped-Asset-1-32x32.png Publication Archives - Iterion Therapeutics https://iteriontherapeutics.com/category/publication/ 32 32 Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo https://pubmed.ncbi.nlm.nih.gov/35159107/#new_tab https://pubmed.ncbi.nlm.nih.gov/35159107/#new_tab#respond Tue, 14 Feb 2023 02:21:21 +0000 https://iteriontherapeutics.com/?p=1510 Ioanna Savvidou, Tiffany Khong, Sophie Whish, Irena Carmichael, Tara Sepehrizadeh, Sridurga Mithraprabhu, Stephen K Horrigan, Michael de Veer, Andrew Spence

The post Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo appeared first on Iterion Therapeutics.

]]> Ioanna Savvidou, Tiffany Khong, Sophie Whish, Irena Carmichael, Tara Sepehrizadeh, Sridurga Mithraprabhu, Stephen K Horrigan, Michael de Veer, Andrew Spence

The post Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/35159107/#new_tab/feed/ 0 The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt) – Dependent Gene Transcription in Cancer through Disruption of the Transducin B-Like 1-B-Catenin Protein Complex https://pubmed.ncbi.nlm.nih.gov/34006586/#:~:text=Catenin%20Protein%20Complex-,The%20Small%20Molecule%20BC%2D2059%20Inhibits%20Wingless%2FIntegrated%20(Wnt,1%2D%20%CE%B2%2DCatenin%20Protein%20Complex#new_tab https://pubmed.ncbi.nlm.nih.gov/34006586/#:~:text=Catenin%20Protein%20Complex-,The%20Small%20Molecule%20BC%2D2059%20Inhibits%20Wingless%2FIntegrated%20(Wnt,1%2D%20%CE%B2%2DCatenin%20Protein%20Complex#new_tab#respond Mon, 27 Jun 2022 14:57:31 +0000 https://iteriontherapeutics.com/?p=1374 Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, Hariprasad Vankayalapati, Alexis Weston, Trason Thode, Kapil N Bhalla, Serina NG, Ryan Rodrigues Del Villar, Kevin Drenner, Mohan R Kaadige, Stephen K Horrigan, Surinder K Batra, Ravi Salgia, Sunil Sharma  

The post The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt) – Dependent Gene Transcription in Cancer through Disruption of the Transducin B-Like 1-B-Catenin Protein Complex appeared first on Iterion Therapeutics.

]]> Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, Hariprasad Vankayalapati, Alexis Weston, Trason Thode, Kapil N Bhalla, Serina NG, Ryan Rodrigues Del Villar, Kevin Drenner, Mohan R Kaadige, Stephen K Horrigan, Surinder K Batra, Ravi Salgia, Sunil Sharma

 

The post The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt) – Dependent Gene Transcription in Cancer through Disruption of the Transducin B-Like 1-B-Catenin Protein Complex appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/34006586/#:~:text=Catenin%20Protein%20Complex-,The%20Small%20Molecule%20BC%2D2059%20Inhibits%20Wingless%2FIntegrated%20(Wnt,1%2D%20%CE%B2%2DCatenin%20Protein%20Complex#new_tab/feed/ 0 NUCLEAR β-CATENIN INHIBITOR – TBL1 – A Novel Target for Safe & Effective Blockade of the Nuclear β-catenin Signaling Pathway& Effective Blockade Of The Nuclear Β-Catenin Signaling Pathway https://drug-dev.com/nuclear-%CE%B2-catenin-inhibitor-tbl1-a-novel-target-for-safe-effective-blockade-of-the-nuclear-%CE%B2-catenin-signaling-pathway/#new_tab https://drug-dev.com/nuclear-%CE%B2-catenin-inhibitor-tbl1-a-novel-target-for-safe-effective-blockade-of-the-nuclear-%CE%B2-catenin-signaling-pathway/#new_tab#respond Tue, 30 Mar 2021 12:35:19 +0000 https://iteriontherapeutics.com/?p=1076 Ruolan Han, PhD

The post NUCLEAR β-CATENIN INHIBITOR – TBL1 – A Novel Target for Safe & Effective Blockade of the Nuclear β-catenin Signaling Pathway& Effective Blockade Of The Nuclear Β-Catenin Signaling Pathway appeared first on Iterion Therapeutics.

]]> Ruolan Han, PhD

The post NUCLEAR β-CATENIN INHIBITOR – TBL1 – A Novel Target for Safe & Effective Blockade of the Nuclear β-catenin Signaling Pathway& Effective Blockade Of The Nuclear Β-Catenin Signaling Pathway appeared first on Iterion Therapeutics.

]]> https://drug-dev.com/nuclear-%CE%B2-catenin-inhibitor-tbl1-a-novel-target-for-safe-effective-blockade-of-the-nuclear-%CE%B2-catenin-signaling-pathway/#new_tab/feed/ 0 Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors https://pubmed.ncbi.nlm.nih.gov/32068780/#new_tab https://pubmed.ncbi.nlm.nih.gov/32068780/#new_tab#respond Tue, 28 Jul 2020 20:52:40 +0000 https://iteriontherapeutics.com/?p=877 Dyana T.Saenz, PhD, Christopher Peter Mill, PhD BA, Warren Fiskus, BSc, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

The post Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors appeared first on Iterion Therapeutics.

]]> Dyana T.Saenz, PhD, Christopher Peter Mill, PhD BA, Warren Fiskus, BSc, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

The post Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/32068780/#new_tab/feed/ 0 Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/30793158/#new_tab https://pubmed.ncbi.nlm.nih.gov/30793158/#new_tab#respond Thu, 21 Feb 2019 18:50:39 +0000 https://iteriontherapeutics.com/?p=463 Motonari Nomura, Nino Rainusso, Yi-Chien Lee, Brian Dawson, Cristian Coarfa, Ruolan Han, Jeffrey L Larson, Ryan Shuck, Lyazat Kurenbekova, Jason T Yustein.

The post Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma appeared first on Iterion Therapeutics.

]]> Motonari Nomura, Nino Rainusso, Yi-Chien Lee, Brian Dawson, Cristian Coarfa, Ruolan Han, Jeffrey L Larson, Ryan Shuck, Lyazat Kurenbekova, Jason T Yustein.

The post Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/30793158/#new_tab/feed/ 0 Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. https://pubmed.ncbi.nlm.nih.gov/30575820/#new_tab https://pubmed.ncbi.nlm.nih.gov/30575820/#new_tab#respond Fri, 21 Dec 2018 11:54:47 +0000 https://iteriontherapeutics.com/?p=206 Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

The post Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. appeared first on Iterion Therapeutics.

]]> Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

The post Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/30575820/#new_tab/feed/ 0 β-catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. https://pubmed.ncbi.nlm.nih.gov/28500235/#new_tab https://pubmed.ncbi.nlm.nih.gov/28500235/#new_tab#respond Sun, 17 Sep 2017 11:58:04 +0000 https://iteriontherapeutics.com/?p=208 Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, Spencer A.

The post β-catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. appeared first on Iterion Therapeutics.

]]> Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, Spencer A.

The post β-catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/28500235/#new_tab/feed/ 0 Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-catenin Pathway Inhibitors. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00460#new_tab https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00460#new_tab#respond Thu, 13 Aug 2015 12:00:34 +0000 https://iteriontherapeutics.com/?p=212 Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S.

The post Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-catenin Pathway Inhibitors. appeared first on Iterion Therapeutics.

]]> Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S.

The post Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-catenin Pathway Inhibitors. appeared first on Iterion Therapeutics.

]]> https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00460#new_tab/feed/ 0 Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. https://pubmed.ncbi.nlm.nih.gov/25482131/#new_tab https://pubmed.ncbi.nlm.nih.gov/25482131/#new_tab#respond Mon, 29 Jun 2015 11:58:57 +0000 https://iteriontherapeutics.com/?p=210 Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.

The post Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. appeared first on Iterion Therapeutics.

]]> Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.

The post Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/25482131/#new_tab/feed/ 0